Focal Nodular Hyperplasia: Solitary or multiple benign hepatic vascular tumors, usually occurring in women of 20-50 years of age. The nodule, poorly encapsulated, consists of a central stellate fibrous scar and normal liver elements such as HEPATOCYTES, small BILE DUCTS, and KUPFFER CELLS among the intervening fibrous septa. The pale colored central scar represents large blood vessels with hyperplastic fibromuscular layer and narrowing lumen.Bile Ducts, Intrahepatic: Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.Adenoma: A benign epithelial tumor with a glandular organization.Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.Bile Ducts: The channels that collect and transport the bile secretion from the BILE CANALICULI, the smallest branch of the BILIARY TRACT in the LIVER, through the bile ductules, the bile ducts out the liver, and to the GALLBLADDER for storage.Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Hemangioma: A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)Adenoma, Liver Cell: A benign epithelial tumor of the LIVER.Norethynodrel: A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and endometriosis. As a contraceptive, it has usually been administered in combination with MESTRANOL.Liver Neoplasms: Tumors or cancer of the LIVER.Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.Glycogen Storage Disease Type I: An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.Adenoma, Bile Duct: A benign tumor of the intrahepatic bile ducts.Hamartoma: A focal malformation resembling a neoplasm, composed of an overgrowth of mature cells and tissues that normally occur in the affected area.Libraries, Digital: Libraries in which a major proportion of the resources are available in machine-readable format, rather than on paper or MICROFORM.Authorship: The profession of writing. Also the identity of the writer as the creator of a literary production.Liver Diseases: Pathological processes of the LIVER.Gastroenterology: A subspecialty of internal medicine concerned with the study of the physiology and diseases of the digestive system and related structures (esophagus, liver, gallbladder, and pancreas).Libraries: Collections of systematically acquired and organized information resources, and usually providing assistance to users. (ERIC Thesaurus, http://www.eric.ed.gov/ accessed 2/1/2008)Library Automation: The use of automatic machines or processing devices in libraries. The automation may be applied to library administrative activities, office procedures, and delivery of library services to users.Library Collection Development: Development of a library collection, including the determination and coordination of selection policy, assessment of needs of users and potential users, collection use studies, collection evaluation, identification of collection needs, selection of materials, planning for resource sharing, collection maintenance and weeding, and budgeting.Granuloma: A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.Cysts: Any fluid-filled closed cavity or sac that is lined by an EPITHELIUM. Cysts can be of normal, abnormal, non-neoplastic, or neoplastic tissues.Hepatomegaly: Enlargement of the liver.Liver: A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.Liver Regeneration: Repair or renewal of hepatic tissue.Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.Hypertension, Portal: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.Hepatectomy: Excision of all or part of the liver. (Dorland, 28th ed)Choledochal Cyst: A congenital anatomic malformation of a bile duct, including cystic dilatation of the extrahepatic bile duct or the large intrahepatic bile duct. Classification is based on the site and type of dilatation. Type I is most common.Pathology, Clinical: A subspecialty of pathology applied to the solution of clinical problems, especially the use of laboratory methods in clinical diagnosis. (Dorland, 28th ed.)Cytodiagnosis: Diagnosis of the type and, when feasible, the cause of a pathologic process by means of microscopic study of cells in an exudate or other form of body fluid. (Stedman, 26th ed)Pancreatic Ducts: Ducts that collect PANCREATIC JUICE from the PANCREAS and supply it to the DUODENUM.Ampulla of Vater: A dilation of the duodenal papilla that is the opening of the juncture of the COMMON BILE DUCT and the MAIN PANCREATIC DUCT, also known as the hepatopancreatic ampulla.Common Bile Duct Neoplasms: Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.Cytological Techniques: Methods used to study CELLS.Bile Ducts, Extrahepatic: Passages external to the liver for the conveyance of bile. These include the COMMON BILE DUCT and the common hepatic duct (HEPATIC DUCT, COMMON).Canada: The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.Biliary Tract Neoplasms: Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.Crisis Intervention: Brief therapeutic approach which is ameliorative rather than curative of acute psychiatric emergencies. Used in contexts such as emergency rooms of psychiatric or general hospitals, or in the home or place of crisis occurrence, this treatment approach focuses on interpersonal and intrapsychic factors and environmental modification. (APA Thesaurus of Psychological Index Terms, 7th ed)Blast Crisis: An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.Contraceptives, Oral: Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both.Thyroid Crisis: A dangerous life-threatening hypermetabolic condition characterized by high FEVER and dysfunction of the cardiovascular, the nervous, and the gastrointestinal systems.Contraceptives, Postcoital: Contraceptive substances to be used after COITUS. These agents include high doses of estrogenic drugs; progesterone-receptor blockers; ANTIMETABOLITES; ALKALOIDS, and PROSTAGLANDINS.Contraceptives, Oral, Combined: Fixed drug combinations administered orally for contraceptive purposes.Caroli Disease: Congenital cystic dilatation of the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC). It consists of 2 types: simple Caroli disease is characterized by bile duct dilatation (ectasia) alone; and complex Caroli disease is characterized by bile duct dilatation with extensive hepatic fibrosis and portal hypertension (HYPERTENSION, PORTAL). Benign renal tubular ectasia is associated with both types of Caroli disease.Sex Chromosomes: The homologous chromosomes that are dissimilar in the heterogametic sex. There are the X CHROMOSOME, the Y CHROMOSOME, and the W, Z chromosomes (in animals in which the female is the heterogametic sex (the silkworm moth Bombyx mori, for example)). In such cases the W chromosome is the female-determining and the male is ZZ. (From King & Stansfield, A Dictionary of Genetics, 4th ed)Muridae: A family of the order Rodentia containing 250 genera including the two genera Mus (MICE) and Rattus (RATS), from which the laboratory inbred strains are developed. The fifteen subfamilies are SIGMODONTINAE (New World mice and rats), CRICETINAE, Spalacinae, Myospalacinae, Lophiomyinae, ARVICOLINAE, Platacanthomyinae, Nesomyinae, Otomyinae, Rhizomyinae, GERBILLINAE, Dendromurinae, Cricetomyinae, MURINAE (Old World mice and rats), and Hydromyinae.Chromosomes: In a prokaryotic cell or in the nucleus of a eukaryotic cell, a structure consisting of or containing DNA which carries the genetic information essential to the cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)Y Chromosome: The male sex chromosome, being the differential sex chromosome carried by half the male gametes and none of the female gametes in humans and in some other male-heterogametic species in which the homologue of the X chromosome has been retained.Chromosome Mapping: Any method used for determining the location of and relative distances between genes on a chromosome.United States

Promoting effects of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone on rat glandular stomach carcinogenesis initiated with N-methyl-N'-nitro-N-nitrosoguanidine. (1/118)

The modifying effects of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX), a mutagenic by-product in chlorinated water, on the development of glandular stomach cancers were investigated in Wistar rats. A total of 120 males, 6 weeks of age, were divided into six groups. After initiation with 100 ppm N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) solution and 5% NaCl diet for 8 weeks, 30 rats each in groups 1-3 were given MX in the drinking water at concentrations of 30, 10, or 0 ppm for the following 57 weeks. Ten animals each in groups 4-6 were administered the MX without prior carcinogen exposure. There were no statistical significant differences in final body weights between the groups. The incidences and multiplicities of adenocarcinomas in the glandular stomachs were significantly higher (P < 0.05) in the initiated 30 ppm MX group than those in the MNNG/NaCl group. The incidences of atypical hyperplasias in the glandular stomachs were also significantly increased (P < 0.05 or 0.01) by the MX treatments. With their multiplicity, the effects were clearly dose dependent. Interestingly, the 30 ppm MX alone itself induced atypical hyperplasias in the pylorus, although the incidences and severity were low. Moreover, MX showed a tendency to enhance the development of intrahepatic cholangiocellular tumors and thyroid follicular cell tumors in the MNNG-treated animals. The results of the present study thus indicate that MX exerts promoting effects when given during the postinitiation phase of two-stage glandular stomach carcinogenesis in rats.  (+info)

Immunohistochemical localization of inducible nitric oxide synthase and 3-nitrotyrosine in rat liver tumors induced by N-nitrosodiethylamine. (2/118)

Human liver cancers have been associated mainly with chronic inflammations such as viral hepatitis B or C. This suggests that prolonged cell damage by chronic inflammation is critical in cancer development. Overproduction of nitric oxide (NO.) and its derivative (NOx, peroxynitrite) has been implicated as a cause of tissue damage by inflammation, thus contributing to tumor promotion. We have demonstrated the expression of the inducible isoform of nitric oxide synthase (iNOS) and 3-nitrotyrosine, a marker of peroxynitrite formation, by immunohistochemistry in preneoplastic and neoplastic rat liver tissues induced by continuous infusion of N-nitrosodiethylamine with mini-pumps. The preneoplastic lesions were characterized by proliferation of phenotypically altered hepatic foci (PAHF), dysplastic hepatocytes and oval cells. Histologically, the tumors were hepatocellular carcinomas (HCCs) of trabecular, (pseudo)glandular and solid types with or without cholangiocellular involvement. iNOS was located mainly in oval cells, capillary endothelial and muscular cells, epithelia of cholangiomas and glandular HCCs. 3-Nitrotyrosine was observed in the cytoplasms of PAHF and dysplastic hepatocytes in preneoplasias and in the cytoplasms of some living or apoptotic HCC cells, connective tissues, proteinaceous fluids, sinusoidal endothelia of tumorous hepatocytes and cholangiomas in tumors. From these observations, we suggest that: (i) chronic tissue damage by chemical carcinogens may act to induce iNOS and peroxynitrite formation; (ii) oval cells play a key role in development and/or growth of tumor tissues by producing NO. via iNOS, which may also cause tissue damage by peroxynitrite; (iii) iNOS can be considered as a phenotypic marker in cells of oval cell lineage and neovascularized capillaries in tumor tissues.  (+info)

Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum. (3/118)

Hepatocellular carcinoma (HCC) is a well-known complication of genetic hemochromatosis (GH). However, the frequency of primary liver carcinoma (PLC) with biliary differentiation, such as cholangiocarcinoma (CC) and combined hepatocholangiocarcinoma (CHCC), in GH remains unclear We analyzed the histologic type of 20 PLCs occurring in the background of GH; all patients were homozygotic for the C282Y mutation. Ten were depleted of iron by successive phlebotomies, while the remaining 10 were untreated. Histologically, 13 cases were classified as HCC, 3 as CC, and 4 as CHCC. Immunohistochemical detection of Hep Par 1, cytokeratin 19 (CK19), and MUC1 supported this classification; PLC with biliary differentiation was immunoreactive for MUC1 in 86% (6/7) of cases and for CK19 in 100% (7/7) of cases. The nontumoral liver exhibited no cirrhosis or extensive fibrosis in 6 cases. Von Meyenburg complexes were present in 11 cases and intraparenchymal bile duct adenomas in 3. These data suggest that PLCs in patients with GH present a wide histologic spectrum, with tumors showing frequent biliary differentiation; may arise on a nonfibrotic or a cirrhotic liver; and often are associated with Von Meyenburg complexes and to a lesser extent with bile duct adenomas.  (+info)

Management strategies in resection for hilar cholangiocarcinoma. (4/118)

Between 1960 and 1990, resection was performed in 23 of 122 patients who underwent surgical treatment for hilar cholangiocarcinoma. Local excision of the lesion alone was performed in 10 cases (43%). Hepatic resection for tumor extending to the secondary bile ducts or hepatic parenchyma was performed in 13 cases (57%): extended right hepatectomy (3), right hepatectomy (1), extended left hepatectomy (6), left hepatectomy (2), and left lobectectomy (1). In three other cases, resection by total hepatectomy and liver transplantation was performed, but these were not included in the analysis of results for resection. Significant operative complications occurred in only two cases (8.7%), and the operative mortality rate was zero. In four cases, complete excision of the tumor could not be achieved macroscopically (macroscopic curative resection rate 19/122; 15.6%). In nine cases, the margins of the resected specimens were free from tumor on histologic examination (microscopic curative resection rate, 9/122; 7.4%). In 10 cases, the resection margins were found to contain tumor on histologic examination. The overall survival rate was 87% at 1 year, 63% at 2 years, and 25% at 3 years (median survival, 24 months). The survival and freedom from recurrence rates for patients with free resection margins was superior to that for patients with involved resection margins or residual macroscopic disease. A potentially curative resection, with histologically negative margins and no recurrence to date, was achieved in seven patients using the following procedures: local excision for two type I lesions; left hepatectomy plus excision of segment 1 for two type IIIb lesions and one type IV lesion; right hepatectomy and right hepatectomy plus excision of segment 1 for two type IIIa lesions. These results indicate that improved survival in hilar cholangiocarcinoma can be achieved by resection, with minimal morbidity and zero mortality rates, if histologically free resection margins are obtained. To achieve this, we recommend the following procedures for each type of lesion, based on our experience and on anatomic considerations: local excision for type I; local excision plus resection of segment 1 for type II; local excision, resection of segment 1, and right or left hepatectomy for types IIIa and b; hepatectomy plus liver transplantation for type IV.  (+info)

Low frequency of p53 gene mutation in tumors induced by aflatoxin B1 in nonhuman primates. (5/118)

Aflatoxin B1 has been suggested as a causative agent for a G to T mutation at codon 249 in the p53 gene in human hepatocellular carcinomas from southern Africa and Qidong in China. To test this hypothesis, nine tumors induced by aflatoxin B1 in nonhuman primates were analyzed for mutations in the p53 gene. These included four hepatocellular carcinomas, two cholangiocarcinomas, a spindle cell carcinoma of the bile duct, a hemangioendothelial sarcoma of the liver, and an osteogenic sarcoma of the tibia. None of the tumors showed changes at the third position of codon 249 by cleavage analysis of the HaeIII enzyme site at codon 249. A point mutation was identified in one hepatocellular carcinoma at the second position of codon 175 (G to T transversion) by sequencing analysis of the four conserved domains (II to V) in the p53 gene. These data suggest that mutations in the p53 gene are not necessary in aflatoxin B1 induced hepatocarcinogenesis in nonhuman primates. The occurrence of mutation in codon 249 of the p53 gene in selective samples of human hepatocellular cancers may indicate involvement of environmental carcinogens other than aflatoxin B1 or that hepatitis B virus-related hepatitis is a prerequisite for aflatoxin B1 induction of G to T transversion in codon 249.  (+info)

Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. (6/118)

To evaluate glucose metabolism in patients with tumors involving the liver, 35 patients with liver lesions had PET using 18F-2-fluoro-2-deoxy-D-glucose (FDG). FDG (148 MBq) was injected and radioactivity of the tumor was scanned dynamically by PET. The rate constants (k1, k2, k3, k4) of FDG in a metabolic model were calculated. The results were compared to hexokinase activity in the excised tumor specimens. k3 was found to reflect tumor hexokinase activity. When k3 was used as an index (cut-off value: 0.025), it was possible to distinguish benign and malignant tumors. k4 was significantly higher in hepatocellular carcinoma. By using k3 and k4 as indices, one could assess the degree of differentiation of hepatocellular carcinoma. After treatment, k3 decreased according to the effectiveness of therapy and thus may be a useful index for quantitatively assessing tumor viability.  (+info)

Analysis of failure after curative irradiation of extrahepatic bile duct carcinoma. (7/118)

Thirty-four patients with subtotally resected or unresectable carcinoma of the extrahepatic bile ducts received radiation therapy; a minimum of 45 Gy (external beam) to the tumor and regional lymph nodes +/- 5-fluorouracil (5-FU). Seventeen patients received an external beam boost of 5 to 15 Gy to the tumor, and a specialized boost was used in the remaining 17 patients (iridium-192 transcatheter seeds in 10 and intraoperative radiation therapy [IORT] with electrons in seven). The median time to death in all 34 patients was 12 months (range, 4 to 98-months). The only patients who survived longer than 18 months were those either with gross total or subtotal resection before external irradiation (2 of 6) or who received specialized boosts (192Ir, 3 of 10; IORT, 3 of 7). Local failure was documented in 9 of 17 patients who received external beam irradiation alone +/- 5-FU, 3 of 10 patients who received an 192Ir boost, and 2 of 6 patients who received an IORT boost with curative intent.  (+info)

Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma. (8/118)

The aim of this study was to evaluate the new monoclonal tumour marker CA 242 in the diagnosis of pancreatic carcinoma and to compare it with the established markers CA 50 and CEA. Serum concentrations were determined in 113 patients with jaundice, in 20 patients with laboratory values suggesting cholestasis, and in 60 patients with a suspicion to have chronic pancreatitis. Twenty-four of these 193 patients had pancreatic carcinoma and two patients had carcinoma of papilla of Vater. The sensitivities of CA 242, CA 50 and CEA were 80.7%, 96.1%, and 92.3%, respectively. The specificities were 79.0%, 58.0%, and 59.2%. The sensitivities of combinations of CA 50 and CEA with CA 242 did not exceed the sensitivity of CA 50 alone. The specificity of CA 242 was improved by combining it with CEA (92.2%). The serum marker CA 242 seems to be less sensitive than CEA and CA 50 in the detection of pancreatic carcinoma, but it may prove useful because of its high specificity.  (+info)

article{8510062, abstract = {Unlike its family member p53, TP63 is rarely mutated in human cancer. However, Delta Np63 alpha protein levels are often elevated in tumors of epithelial origin, such as squamous cell carcinoma and cholangiocarcinoma. To study the oncogenic properties of Delta Np63 alpha in vivo, we generated transgenic mice overexpressing Delta Np63 alpha from the Rosa26 locus promoter controlled by keratin 5-Cre. We found that these mice spontaneously develop epidermal cysts and ectopic Delta Np63 alpha expression in the bile duct epithelium that leads to dilatation of the intrahepatic biliary ducts, to hepatic cyst formation and bile duct adenoma. Moreover, when subjected to models of 7,12-dimethylbenz[a]anthracene-based carcinogenesis, tumor initiation was increased in Delta Np63 alpha transgenic mice in a gene dosage-dependent manner although Delta Np63 alpha overexpression did not alter the sensitivity to 7,12-dimethylbenz[a] anthracene-induced cytotoxicity in vivo. However, ...
Primary benign tumors of the liver, other than angiomas, are rare. Hoffman1 reviewed the literature in 1942 and was able to find only 58 cases reported. He added one case of his own. No attempt was made to classify these lesions.. Primary benign liver tumors may arise from either the liver cells or the bile duct epithelium. These are classified as liver cell adenomas or bile duct adenomas. In addition, a third type of tumor occurs. This lesion is composed of both liver cells and bile ducts. Such lesions have been classified by Warvi2 as. ...
TY - JOUR. T1 - Benign hepatocellular tumors. AU - Guzman, Ignacio J.. AU - Gold, Jay H.. AU - Rosai, Juan. AU - Schneider, Philip D.. AU - Varco, Richard L.. AU - Buchwald, Henry. PY - 1977/10. Y1 - 1977/10. N2 - This series summarizes all cases diagnosed as benign hepatocellular tumors occurring at the University of Minnesota Hospitals from 1950 to 1976. Excluding hemangiomas, 40 tumors were reviewed and reclassified. Eighteen were diagnosed as focal nodular hyperplasia (FNH), 10 as hepatocellular adenomas (HCS), 11 as bile duct adenomas (BDA), and one as a mesenchymal hamartoma. FNH: The female: male ratio was 8:1, and the mean age was 43 years ±18 (SD). Two patients were symptomatic; of these, one presented with portal hypertension. Treatment consisted of local resection in 12, left hepatectomy in one, and right hepatectomy in two. Eight patients had a history of oral contraceptive or other steroid intake. The tumors occurring after 1964 were larger (p , 0. 05). HCA: The female: male ratio ...
Yun‐Yong Park, Sang‐Bae Kim, Hee Dong Han, Bo Hwa Sohn, Ji Hoon Kim, Jiyong Liang, Yiling Lu, Cristian Rodriguez‐Aguayo, Gabriel Lopez‐Berestein, Gordon B. Mills, Anil K. Sood, Ju‐Seog ...
Jae‐Kyung Won, Su Jong Yu, Chae Young Hwang, Sung‐Hwan Cho, Sang‐Min Park, Kwangsoo Kim, Won‐Mook Choi, Hyeki Cho, Eun Ju Cho, Jeong‐Hoon Lee, Kyung Bun Lee, Yoon Jun Kim, Kyung‐Suk Suh, Ja‐June Jang, Chung Yong Kim, Jung‐Hwan Yoon, Kwang‐Hyun ...
There is no known effective treatment for cats and dogs with nodular and diffuse liver tumors as liver tumors are generally considered resistant to chemotherapy and radiation therapy. However, three-dimensional conformal radiation therapy has been reported with objective responses in five of six dogs and minimal acute radiation effects; and the use of adjuvant gemcitabine in dogs with incompletely excised massive HCC, nodular HCC, and diffuse HCC has been reported in 18 dogs with good results.. Palliative treatment options, especially for nodular and diffuse hepatic tumors, include, microwave ablation, embolization, and chemoembolization, but these modalities are not widely available.. PROGNOSIS. The prognosis following surgical resection of massive HCC in dogs and bile duct adenomas in cats is very good. The majority of cats and dogs are cured. In one study of 42 dogs with massive HCC treated with liver lobectomy, two dogs (5%) died intraoperatively secondary to blood loss as a result of ...
লিভার ক্যান্সার(ইংরেজি: Liver cancer) এর অপর নাম হেপাটিক ক্যান্সার (Hepatic cancer) ও প্রাইমারি হেপাটিক ক্যান্সার (primary hepatic cancer), একে বাংলায় যকৃতের ক্যান্সার বলে। যকৃৎ ক্যান্সারের উৎপত্তি যকৃতেই হয়।[১] অন্য অঙ্গ থেকে ক্যান্সার কোষ লিভারে ছড়ালে তাকে লিভার মেটাস্টাসিস বলে।[২] লিভার ক্যান্সারে বক্ষপিঞ্জরের নিচে ডানপাশে দলা বা ব্যথা অনুভূত হয়।অন্যান্য লক্ষণের মধ্যে রয়েছে জন্ডিস, ওজন কমে যাওয়া, ...
These findings are partly in agreement with the current literature. In particular, incidence of hepatic cancer (11), breast cancer (13), and pancreatic cancer (12) has been reported to be higher in patients with diabetes, although the causal role of diabetes in the pathogenesis of the latter cancer has been recently questioned (26).. There is no straightforward explanation for the excess mortality from hepatic cancer in diabetic patients, but several hypotheses can be suggested. First, mortality from cirrhosis is nearly three times higher in patients with type 2 diabetes than in the general population (19). Hepatitis infections could have contributed to the increased mortality from both cirrhosis and hepatic cancer, as a high prevalence of the hepatitis C virus has been reported in diabetic patients (27). Also, alcohol consumption could contribute to the excess mortality from hepatic cancer: in the Paris Prospective Study (28), risk of death from alcohol-related diseases was high in men with ...
Siragen Pharmaceuticals, a spin-off from NeuroGeneration, is developing small-molecule kinase inhibitors for the treatment of prostate and hepatic cancers.
TY - JOUR. T1 - Histopathological characteristics of hypervascular cholangiocellular carcinoma as an early stage of cholangiocellular carcinoma. AU - Sato, Yuya. AU - Ojima, Hidenori. AU - Onaya, Hiroaki. AU - Mori, Taisuke. AU - Hiraoka, Nobuyoshi. AU - Kishi, Yoji. AU - Nara, Satoshi. AU - Esaki, Minoru. AU - Shimada, Kazuaki. AU - Kosuge, Tomoo. AU - Sugihara, Kenich. AU - Kanai, Yae. PY - 2014/10/1. Y1 - 2014/10/1. N2 - Aim: Prognosis of hypervascular cholangiocellular carcinoma (h-CCC) is reportedly better than that of ordinary hypovascular CCC (o-CCC). The aim of this study is to clarify the histopathological characteristics of h-CCC. Methods: On the basis of the findings in the arterial phase of contrast-enhanced computed tomography, 16 cases of mass-forming-type CCC were divided into two groups (h-CCC, n=8; o-CCC, n=8). Areas of high (Area H-a) and low (Area H-b) attenuation in h-CCC cases and areas of low attenuation in o-CCC cases (Area O) were delineated. These areas were then ...
Tumor staging of extrahepatic bile duct (EBD) carcinoma is problematic for a number of reasons, including definitional problems with the current T classification of the American Joint Committee on Cancer staging system and the common occurrence of severe desmoplastic stromal reaction around the adva
Biliary cystadenomas are uncommon benign cystic neoplasms of the liver. Epidemiology Biliary cystadenomas occur predominantly in middle-aged patients and are more common in women 1. Clinical presentation The clinical presentation of biliary c...
My mother died of Cholangiocarcinoma. This is a very uncommon cancer of the bile duct. I have since that day, started this site. Not until today did I look up Cholangiocarcinoma specifically. What I just found astounds me... Was Mom taking a trial drug? A drug that wasnt even approved by the FDA? She…
Liver transplantation is a treatment option for combined hepatocellular and cholangiocellular carcinoma (cHCC-CC) but its prognostic significance remains unclear. The present study aimed to evaluate the therapeutic effects of liver transplantation on cHCC-CC and analyze the clinicopathological factors affecting prognosis. Retrospective analysis of the clinicopathological data of a case series of 21 patients with cHCC-CC who underwent orthotopic liver transplantation from April 2000 to April 2011 was performed. Cumulative survival rate and tumor-free survival rate were calculated using the Kaplan-Meier method followed by the log-rank test. The operative survival rate of the 21 patients was 100%; the 30 day mortality was 4.8% (1/21) and 90-day mortality was 9.5% (2/21); 1-, 2-, 3-, and 5-year overall cumulative survival rates were 64%, 47%, 39%, and 39%, respectively; and the corresponding cumulative tumor-free survival rates were 64%, 37%, 30%, and 30%, respectively. Cumulative tumor diameter, lymph node
Biliary cystadenomas are benign but potentially malignant cystic neoplasms, which classically contain mesenchymal stroma similar to ovarian tissue. We report a case of an extra-hepatic biliary cystadenoma with mesenchymal stroma along with a discussi
Cholangiocarcinomas (CC) frequently demonstrate lymphatic spread. We investigated lymph node (LN) counts after resection of extrahepatic CC and survival based on the SEER 1973-2004 database. Out of 20
Cholangiocellular Carcinoma in Dogs Bile duct carcinoma is a malignant cancer that typically arises from the the epithelia, the cellular lining of the hepatic (
Cholangiocarcinomas are a heterogeneous group of malignancies arising from a number of cells of origin along the biliary tree. Although most cases in Western countries are sporadic, large population-based studies have identified a number of risk factors. This review summarises the evidence behind reported risk factors and current understanding of the molecular pathogenesis of cholangiocarcinoma, with a focus on inflammation and cholestasis as the driving forces in cholangiocarcinoma development. Cholestatic liver diseases (e.g. primary sclerosing cholangitis and fibropolycystic liver diseases), liver cirrhosis, and biliary stone disease all increase the risk of cholangiocarcinoma. Certain bacterial, viral or parasitic infections such as hepatitis B and C and liver flukes also increase cholangiocarcinoma risk. Other risk factors include inflammatory disorders (such as inflammatory bowel disease and chronic pancreatitis), toxins (e.g. alcohol and tobacco), metabolic conditions (diabetes, obesity and non
Cholangiocarcinomas (bile duct cancers) arise from the epithelial cells of the bile ducts. Although they are rare in the United States, these cancers are highly lethal because most are locally advanced at presentation. (See.)The clinical manifestatio
Find the best cholangiocarcinoma doctors in Kolkata. Get guidance from medical experts to select cholangiocarcinoma specialist in Kolkata from trusted hospitals - credihealth.com
Did you know what is liver cancer is? Liver cancer is also known as hepatic cancer. It is a condition which happens when normal cells in the liver
Bile duct cancer information with its causes along with various treatments available. A parasitic infection called the liver fluke is known to be responsible for causing the bile duct cancer. Detailed description of bile duct cancer symptoms also given.
Find the best bile duct cancer doctors in Bangalore. Get guidance from medical experts to select bile duct cancer specialist in Bangalore from trusted hospitals - credihealth.com
What is Bile Duct Cancer (Cholangiocarcinoma)? Get the facts about Bile Duct Cancer (Cholangiocarcinoma) symptoms, testing, treatment and care options from trusted sources.
[504 Pages Report] Check for Discount on Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016 report by Global Markets Direct. Global Markets Directs, Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review,...
Cancer of the bile duct (also called cholangiocarcinoma) is extremely rare. The true incidence of bile duct cancer is unknown, however, because establishing an accurate diagnosis is difficult. Traditionally, bile duct tumors located within the liver have been classified with hepatocellular carcinoma as primary liver...
There are several bile duct cancer treatment and preventive procedures to administer to patients of bile duct cancer. Treatments would vary depending on th
For cases of inoperable bile duct carcinoma, we perform intraluminal irradiation using an 192iridium wire following endoprostheses implantation. However, the effectiveness of this procedure is uncertain, and may lead to decreased patient quality of life in some cases. Therefore, we obtained samples of bile duct carcinoma either by percutaneous transhepatic cholangioscope (PTCS) or by surgery, and studied whether expression levels of Ki-67 and p53 in these tissues could predict the effectiveness of radiotherapy (RT). Immunohistochemistry was used to determine the expression of p53 and Ki-67 in 40 resected and 18 biopsy specimens. All biopsy specimens were stage IVA according to UICC classification. Labeling indices were calculated as percentage of positively stained tumor cell nuclei of total tumor cells counted. Samples were divided into two groups according to labeling index (LI). In the resected specimens, Ki-67 LI was significantly higher in cases positive for lymphatic invasion than in ...
Cholangiocarcinoma, also known as bile duct cancer, is often treated the same way as hepatocellular carcinoma, the most common form of primary liver cancer that develops in the main type of liver cell.
The original observations of this study relate to inflammation, NO production, DNA damage, and inhibition of DNA repair as related mechanisms for the development and/or progression of cholangiocarcinoma. Our results directly demonstrate the following: (a) human cholangiocarcinomas express the iNOS protein; (b) proinflammatory cytokines stimulate iNOS message and protein expression and the production of NO in cholangiocarcinoma cell lines; (c) the magnitude of NO produced is sufficient to cause single-stranded, double-stranded, and oxidative DNA lesions in the malignant cell lines; and (d) stimulated NO generation is associated with impaired global DNA repair activity in the cholangiocarcinoma cell lines. These data suggest that NO generated in response to inflammation may initiate malignant transformation of biliary epithelia and/or promote progression of established cholangiocarcinoma. Each of these observations is discussed in greater detail below.. iNOS expression with NO generation has been ...
Learn more about Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®) (Patients) from the National Cancer Institute at Siteman Cancer Center.
Hi,. My mom was just diagnosed with Bile Duct Cancer.. I am in departed need of anyone who has dealt with this type of cancer, or any ones family members who had this. I also would love to hear from people who has beat this type of cancer... this has been a world-wind we never ever expected this to happen; especially in November we was told NO-Cancer!! My mom is my life; we are best friends she lives not even a mile from me. I am so hurt, mad & even angry. I have never ever felt so alone in my LIFE... I will be by my mothers side every-step of the way... I want any suggestions on how to cope with all feelings I am felling. Please help!!!! ...
Chemotherapy (chemo) is a treatment of cancer-killing drugs used to kill bile duct cancer cells. Learn more about chemotherapy here.
Bile duct cancer diagnosis (costs for program #33463) ✔ Sana Hospital Duisburg ✔ Department of Internal Medicine II (Gastroenterology and Hepatology) ✔ BookingHealth.com
besides traditional surgery, chemotherapy and radiotherapy for bile duct cancer treatment, there are still integrated combination of TCM and western medicines as well as interventional therapy.
You cant change the fact that you had bile duct cancer, but you can change how you live the rest of your life by making healthy lifestyle choices.
We value your privacy. Your user session will expire in 2 minutes. To stay logged in, please refresh the page or, if you are ...
In bile duct cancer, the cancerous cells may release certain chemicals that can be detected using blood tests. These are known as tumour markers.. But tumour markers can also be caused by other conditions, so this test cant be used to say for certain whether or not you have bile duct cancer.. ...
Sigma-Aldrich offers abstracts and full-text articles by [Srilatha Badaboina, Hyoung-Woo Bai, Yun Hee Na, Chul-Hong Park, Tae Hoon Kim, Tae-Hoon Lee, Byung Yeoup Chung].
... , Yawen Deng, Rihui Zhong, Xiaoying Xie, Xuxia Xiong, Jian He, Linhui Peng, Hua Zeng,
Liver Cancer is also often referred to as Hepatic Cancer and is cancer that starts in the Liver. Cancer that starts in the liver is actually less common than cancer that moves (metastasis) from other parts of the body into the liver.
2008 is soon a wrap, and its time to update my list of the different diagnostic and cancer treatment videos Ive filmed for the www.oncolex.no project over the last three and a half years. The project is almost completed, but I still have some filming related to liver-, pancreatic-, gall bladder- and bile duct cancer…
This phase II trial studies how well atezolizumab with or without cobimetinib works in treating patients with bile duct cancer that has spread to other places
Surgery is the main treatment for extrahepatic bile duct cancer, when possible. Surgery is used to: potentially cure resectable extrahepatic bile duct cancer by completely removing it Surgery is the most effective treatment for extrahepatic bile duct cancer. reduce pain or relieve symptoms or blocka
Hepatocellular carcinoma (liver cell cancer) is the most common type of primary liver cancer. It is relatively rare in the United States but very common in Southeast Asia, especially China. The tumor predominantly affects males who are over 50 years of age, although it may arise in younger individuals or even children. The liver is also the primary site for cholangiocarcinomas (intrahepatic bile duct cancers) that are relatively rare and account for 10-20% of all primary liver cancers. These tumors occur in older individuals, usually after the age of 60. The overall median survival for hepatocellular carcinoma is 4 months and the overall 5-year survival rate is 3%. Cholangiocarcinomas have an overall mean survival time of less than 2 years. Several predisposing factors are thought to play a role in hepatocellular carcinoma. These include infection with hepatotropic viruses such as hepatitis B and C viruses, liver cirrhosis, liver cell dysplasia, exposure to aflatoxins and inborn errors of ...
Final Symptoms Of Liver Cancer , Healthfully. Choose whole-grain breads, pastas, and cereals instead of refined grains.The exocrine group is dominated by pancreatic adenocarcinoma (variations of this name may add invasive and ductal), which is by far the most common type, representing about 85% of all pancreatic cancers.Surgery may be needed in some situations.10 Conditions Treatable with Medical Marijuana.It can also make a persons urine a dark color and make bowel movements pale.Your doctor usually puts in a tube (stent) to open up the blockage, which helps to relieve symptoms.HIPEC can be more effective than other medicines to treat cancer in the abdomen.Optimized by Phoenix Arizona SEO CompanyOptimizex.It would be removed in hours. A tumor in the bile duct can block the flow of bile into the intestine and the bile that is accumulated in the ducts causes the skin to turn yellow.. Controlling Symptoms Of Advanced Cancer , Bile Duct Cancer .... Use the menu to see other pages.Sep 01, 2012A ...
Bile duct cancer starts in the cells of a bile duct. Learn about symptoms, diagnosis, treatment and risks in our guide to bile duct cancer.
Cholangiocarcinoma (CCA) is an uncommon adenocarcinoma arising from the neoplastic transformation of cholangiocytes, the epithelial cells lining the intra-hepatic and extra-hepatic bile ducts. CCA accounts for about 3% of all digestive tumours and 10-15% of the hepatobiliary tumours. It has an annual incidence of 1-2 cases per 100,000 in the Western World, but rates of CCA have been steadily rising worldwide over the past several decades. On a global scale, CCA is the second most common primary hepatic malignancy These tumours have a poor overall survival with a 5-year survival of about 5%. Over 50% of patients present with advanced-stage disease, and the prognosis is poor with the survival of between 6-12 months for unresected patients, even after biliary decompression. CCA may arise anywhere in the biliary tree, from the small, peripheral hepatic ducts to the distal common bile duct. Commonly used classification systems utilise anatomical location to group tumours into three main categories: ...
Learn about bile duct cancer (cholangiocarcinoma) from the Cleveland Clinic, including information on treatment options, stages & more.
The purpose of this project is to evaluate the role of gadoxetate (Eovist) enhanced dual-energy CT in better evaluating perihilar cholangiocarcinoma, by exploiting the combination of the physiologic behavior of gadoxetate in liver tissue combined with the advantageous mass attenuation coefficient of Gadolinium achievable through dual energy technique. This combination of unique CT imaging sensitivity, high resolution and differential enhancement potentially allows improved visualization and detection of tumor relative to enhancing surrounding hepatic parenchyma and ductal anatomy in the hepatobiliary phase, due to the biliary excretion of the agent.. Cholangiocarcinoma is a hepatic adenocarcinoma that arises from the bile duct epithelium and is the second most prevalent liver cancer after hepatocellular carcinoma. The hilar intrahepatic variety of cholangiocarcinoma can present as an infiltrative, exophytic, or polypoid lesion. Most extra-hepatic cholangiocarcinomas are infiltrative, causing a ...
... to evaluate for adenomas of the common bile duct; small-bowel imaging when duodenal adenomas are detected or prior to colectomy ... may be necessary to evaluate for adenomas of the common bile duct; annual physical examination with palpation of the thyroid ... medulloblastoma] ,1%; Liver hepatoblastoma 1.6%; Bile ducts adenocarcinoma Low but increased; Stomach adenocarcinoma ,1% in ... Colectomy is usually advised when more than 20 or 30 adenomas or multiple adenomas with advanced histology have developed". " ...
Malignant neoplasm of liver and intrahepatic bile ducts. The most frequent forms are metastatic malignant neoplasm of liver) ... hepatic adenomas, and focal nodular hyperplasia (FNH). Chronic liver diseases like chronic hepatitis, chronic alcohol abuse or ... of liver malignant neoplasm of the gallbladder malignant neoplasm of other parts of biliary tract extrahepatic bile duct ...
... malignant M8160/0 Bile duct adenoma (C22.1, C24.0) Cholangioma (M8160/3) Cholangiocarcinoma (C22.1, C24.0) Bile duct carcinoma ... benign Mesonephric adenoma Wolffian duct adenoma M9110/1 Mesonephric tumor, NOS Wolffian duct tumor M9110/3 Mesonephroma, ... Black adenoma Pigmented adenoma M8373/0 Adrenal cortical adenoma, clear cell (C74.0) M8374/0 Adrenal cortical adenoma, ... Infiltrating duct adenocarcinoma Duct adenocarcinoma, NOS Duct carcinoma, NOS Duct cell carcinoma Ductal carcinoma, NOS M8501/2 ...
Bile duct cystadenoma (8161) Endometrioid cystadenoma (8380) Appendiceal mucinous cystadenoma The term "cystadenoma" may also ... Cystadenoma (or "cystoma") is a type of cystic adenoma. When malignant, it is called cystadenocarcinoma. When not otherwise ...
bile duct: Cholangiocarcinoma. *Klatskin tumor. *gallbladder: Gallbladder cancer. Pancreas. *exocrine pancreas: Adenocarcinoma ... Hepatocellular adenoma (also known as hepatic adenoma or hepadenoma) is a rare, benign liver tumor. It most commonly occurs in ... The histologic diagnosis of hepatic adenomas can be aided by reticulin staining. In hepatic adenomas, the reticulin scaffold is ... Pregnancy could cause the adenoma to grow faster, so patients with hepatic adenomas should avoid pregnancy.[10] ...
... gastrointestinal Colon cancer Extrahepatic bile duct cancer Gallbladder cancer Gastric (stomach) cancer Gastrointestinal ... Bronchial adenomas/carcinoids Small cell lung cancer Mesothelioma Non-small cell lung cancer Pleuropulmonary blastoma Laryngeal ... which suggests that it has originated in the milk ducts.[citation needed] Benign tumors (which are not cancers) are usually ... Cerebral astrocytoma malignant glioma Medulloblastoma Neuroblastoma Oligodendroglioma Pineal astrocytoma Pituitary adenoma ...
... can also form from other structures within the liver such as the bile duct, blood vessels and immune cells. Cancer ... which is a misnomer because adenomas are usually benign). HCC is a cancer formed by liver cells, known as hepatocytes, that ... The majority of cholangiocarcimas occur in the hilar region of the liver, and often present as bile duct obstruction. If the ... "SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct Cancer". NCI. Archived from the original on 2017-07-28. Retrieved 2016 ...
Liver Intrahepatic bile ducts (D13.5) Extrahepatic bile ducts (D13.6) Pancreas (D13.7) Endocrine pancreas Islet cell tumour ... Pituitary gland Pituitary adenoma Prolactinoma (D35.3) Craniopharyngeal duct (D35.4) Pineal gland (D35.5) Carotid body (D35.6) ... Malignant neoplasms of liver and intrahepatic bile ducts (C22.0) Liver cell carcinoma (C22.1) Intrahepatic bile duct carcinoma ... Lacrimal gland and duct (C69.6) Orbit (C69.7) Overlapping lesion of eye and adnexa (C70) Malignant neoplasm of meninges (C70.0 ...
Injury to hepatocyte and bile duct cells lead to accumulation of bile acid inside the liver. This promotes further liver damage ... Hepatocellular carcinoma, angiosarcoma, and liver adenomas are the ones usually reported. Causes: Vinyl chloride, combined oral ... it can produce features similar to primary biliary cirrhosis due to progressive destruction of small bile ducts (Vanishing duct ... diclofenac Cholestasis Liver injury leads to impairment of bile flow and cases are predominated by itching and jaundice. ...
... common bile duct neoplasms MeSH C06.130.320.120 --- bile duct neoplasms MeSH C06.130.320.120.280 --- common bile duct neoplasms ... adenoma, islet cell MeSH C06.301.761.249.500 --- insulinoma MeSH C06.301.761.500 --- carcinoma, islet cell MeSH C06.301.761.500 ... File "2006 MeSH Trees".) MeSH C06.130.120.120 --- bile duct neoplasms MeSH C06.130.120.120.280 --- common bile duct neoplasms ... bile duct neoplasms MeSH C06.301.120.250.250 --- common bile duct neoplasms MeSH C06.301.120.401 --- gallbladder neoplasms MeSH ...
The majority of cholangiocarcimas occur in the hilar region of the liver, and often present as bile duct obstruction. If the ... The size of adenomas range from 1 to 30 cm. Symptoms associated with hepatic adenomas are all associate with large lesions ... Hepatic adenomas: These benign epithelial liver tumors develop in the liver and are also an uncommon occurrence, found mainly ... Over the last few decades there has been an increase with occurrences of this specific type of adenoma. The prognosis for these ...
... of the biliary system is called cholescintigraphy and is done to diagnose obstruction of the bile ducts by a ... Tc99m-sestamibi is used to detect parathyroid adenomas. To detect metastases/function of thyroid, the isotopes iodine-131 or ... The radiopharmaceutical then goes into the bile ducts, the gallbladder, and the intestines. The gamma camera is placed on the ... It can also diagnose gallbladder diseases, e.g. bile leaks of biliary fistulas. In cholescintigraphy, the injected radioactive ...
... adenoma, acidophil MeSH C04.557.470.035.075 --- adenoma, basophil MeSH C04.557.470.035.085 --- adenoma, bile duct MeSH C04.557. ... bile duct neoplasms MeSH C04.588.274.120.250.250 --- common bile duct neoplasms MeSH C04.588.274.120.401 --- gallbladder ... adenoma, liver cell MeSH C04.557.470.035.140 --- adenoma, oxyphilic MeSH C04.557.470.035.155 --- adenoma, pleomorphic MeSH ... adenoma, acidophil MeSH C04.557.465.625.650.075 --- adenoma, basophil MeSH C04.557.465.625.650.095 --- adenoma, chromophobe ...
Bile duct obstruction by gallstones, hepatitis, cirrhosis or cancer should be suspected. About 5% of the population has ... parathyroid adenoma, hyperplasia, or secondary hyperparathyroidism from vitamin D deficiency or renal disease), 4) in cases of ... Obstruction can be located either within the liver or in the bile duct). The diagnosis is narrowed down further by evaluating ... ALP levels in plasma rise with large bile duct obstruction, intrahepatic cholestasis, or infiltrative diseases of the liver. ...
... a yellowing of the skin and eyes caused by obstruction of the bile duct), or weight loss. These signs and symptoms are not ... Pancreatic serous cystadenoma, also known as serous cystadenoma of the pancreas and serous microcystic adenoma, a benign tumour ... The cysts do not communicate with the larger pancreatic ducts. In some cases a fine needle aspiration (FNA) biopsy can be ...
Cholangiocarcinoma, or bile duct cancer Vaginal cancer Cancer of the urachus Stomach cancer Prostate Cancer The term ... Next, they suggested that k-Ras becomes activated and the polyp becomes a small, benign adenoma. The adenoma, lacking the " ... Adenocarcinoma is the malignant counterpart to adenoma, which is the benign form of such tumors. Sometimes adenomas transform ... The gastroenterologist uses a colonoscopy to find and remove these adenomas and polyps to prevent them from continuing to ...
Other primary sites that have been reported include colon, rectum, stomach, gallbladder, bile ducts, small intestine, urinary ... 2007) argued that continued use of non-malignant terms, i.e., adenoma, for those frequent cases with low-grade features (such ... Bradley states that an adenoma, by definition, is a tumor confined to the appendiceal mucosa with absolutely no evidence of ... proposed separating pseudomyxoma peritonei cases into two diagnostic categories: adenoma (disseminated peritoneal ...
... bile duct or pancreatic), urinary tract cancers, prostate cancer and brain tumours were as follows: for MLH1 mutations the risk ... Colorectal cancer Endometrial carcinoma Digestive adenoma: gastric adenoma, pyloric gland adenoma, duodenal adenoma, intestinal ... "Pyloric gland adenoma in Lynch syndrome". The American Journal of Surgical Pathology. 38 (6): 784-92. doi:10.1097/PAS. ... adenoma Ovarian serous cystadenocarcinoma Individuals with HNPCC have about an 80% lifetime risk for colon cancer. Two-thirds ...
bile duct: Cholangiocarcinoma. *Klatskin tumor. *gallbladder: Gallbladder cancer. Pancreas. *exocrine pancreas: Adenocarcinoma ... as opposed to adenoma for example), not to the age of the affected person.[1] While the majority of the polyps found in ... AMHR2 (Persistent Müllerian duct syndrome II). *TGF beta receptors: Endoglin/Alk-1/SMAD4 (Hereditary hemorrhagic telangiectasia ...
bile duct: Cholangiocarcinoma. *Klatskin tumor. *gallbladder: Gallbladder cancer. Pancreas. *exocrine pancreas: Adenocarcinoma ... Nagata J, Kijima H, Hasumi K, Suzuki T, Shirai T, Mine T (June 2003). "Adenocarcinoma and multiple adenomas of the large ...
This results when a cancer in the head of the pancreas obstructs the common bile duct as it runs through the pancreas.[30] ... benign: Hepatocellular adenoma. *Cavernous hemangioma. *hyperplasia: Focal nodular hyperplasia. *Nodular regenerative ... Liver function tests can show a combination of results indicative of bile duct obstruction (raised conjugated bilirubin, γ- ... and attaching a loop of jejunum to the cystic duct to drain bile ("cholecysto-jejunostomy"). It can be performed only if the ...
bile duct: Cholangiocarcinoma. *Klatskin tumor. *gallbladder: Gallbladder cancer. Pancreas. *exocrine pancreas: Adenocarcinoma ... benign: Hepatocellular adenoma. *Cavernous hemangioma. *hyperplasia: Focal nodular hyperplasia. *Nodular regenerative ...
bile duct: Cholangiocarcinoma. *Klatskin tumor. *gallbladder: Gallbladder cancer. Pancreas. *exocrine pancreas: Adenocarcinoma ... benign: Hepatocellular adenoma. *Cavernous hemangioma. *hyperplasia: Focal nodular hyperplasia. *Nodular regenerative ...
bile duct: Cholangiocarcinoma. *Klatskin tumor. *gallbladder: Gallbladder cancer. Pancreas. *exocrine pancreas: Adenocarcinoma ... Adenomas/. adenocarcinomas. (8140-8429). Gastrointestinal. *tract: Linitis plastica. *Familial adenomatous polyposis. *pancreas ...
... of the biliary system is called cholescintigraphy and is done to diagnose obstruction of the bile ducts by a ... Tc99m-sestamibi is used to detect parathyroid adenomas.[5] Thyroid[edit]. Main article: Radioactive iodine uptake test ... The radiopharmaceutical then goes into the bile ducts, the gallbladder, and the intestines. The gamma camera is placed on the ... the injected radioactive chemical is taken up by the liver and secreted into the bile. ...
An important function is the production and control of bile acids. Too much bile acid can be toxic to cells and its synthesis ... The effect of vasopressin on the kidney tubules is to reabsorb water from the distal convoluted tubules and collecting ducts, ... over-production of parathyroid hormone by a parathyroid adenoma resulting in the typically features of hyperparathyroidism, ... Palmer, LG; Frindt, G (2000). "Aldosterone and potassium secretion by the cortical collecting duct". Kidney International. 57 ( ...
... and adenomas of the gallbladder, extrahepatic bile ducts and ampulla of Vater than previously. These lesions are discussed in ... extrahepatic bile ducts and Vaterian system. Because of the increasing number of laparoscopic cholecystectomies and Whipple ...
Contains bile duct elements. *Presence of fibrous tissue formation. *Contains Kupffer cells ... 60% of focal nodular hyperplasia lesions would uptake this radiotracer, which is frequently seen in hepatic adenomas. ... This diagnostic procedure enables the clinician to differentiate the condition from hepatic adenoma or other liver conditions. ... indicating that the lesion is FNH in nature rather than an adenoma. ...
The bile duct can become obstructed when the bile becomes very thick (inspissated bile plug syndrome, IBPS) or when gall stones ... part 2 Physical activity, obesity, and risk for colon cancer and adenoma in men ... Eight of the infants required surgery to clear the bile duct. Drainage of the biliary tract was required in six cases, and the ... Jaundice can be caused by an obstruction in the duct or tube that carries bile from the gallbladder to the small intestine. ...
BILE DUCT PROBLEMS (OBSTRUCTION, HYDROPS, PERFORATION, FISTULA). *CHOLANGITIS - INFLAMMATION / BACTERIAL INFECTION OF THE ... 60% of focal nodular hyperplasia lesions would uptake this radiotracer, which is frequently seen in hepatic adenomas. ... BILE DUCT PROBLEMS (OBSTRUCTION, HYDROPS, PERFORATION, FISTULA). *CHOLANGITIS - INFLAMMATION / BACTERIAL INFECTION OF THE ... As it does so, the liver secretes bile that ends up back in the intestines. The liver also makes proteins important for blood ...
"Bile duct adenoma". Show Diagnoses. Week 181: Case 4. Diagnosis: Bile duct adenoma Week 15: Case 6. Diagnosis: Bile duct ...
Build: Fri Jul 27 09:23:34 EDT 2018 (commit: a5c8d99). National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-435-0888. ...
INTRAHEPATIC BILE DUCT ADENOMA: A DIAGNOSTIC DILEMMA. Case Presentation: A 52-year-old male presented for an evaluation of ... Comments Off on INTRAHEPATIC BILE DUCT ADENOMA: A DIAGNOSTIC DILEMMA ...
Adenoma, Bile Duct / diagnosis. Adenoma, Bile Duct / metabolism. Bile Ducts, Extrahepatic / metabolism. Bile Ducts, ... Bile duct adenoma with oncocytic features.. *[MeSH-major] Adenoma, Bile Duct / pathology. Bile Duct Neoplasms / pathology. Bile ... A case of intrahepatic bile duct adenoma].. *[MeSH-major] Adenoma, Bile Duct / diagnosis. Bile Duct Neoplasms / diagnosis. Bile ... Bile Duct / complications. Adenoma, Bile Duct / diagnosis. Adult. Aged. Bile Duct Neoplasms / complications. Bile Duct ...
... adenoma, Focal Nodular Hyperplasia (FNH), Bile Duct Adenoma (BDA) and Lymphoproliferative Disorders (LPD) including ... and the size of the small bile ducts of the nodule was almost the same as that of the interlobular bile ducts in the background ... 2016) Bile duct adenoma in patient with chronic hepatitis C - As a benign neoplasm by pathological and imaging studies - Pathol ... We encountered two cases of pseudolymphoma of the liver and two of bile duct adenoma features of which were compared with those ...
MeSH-minor] Adenoma, Bile Duct / chemically induced. Adenoma, Bile Duct / pathology. Administration, Oral. Animals. Bile Duct ... Bile Duct / ultrasonography. Bile Duct Diseases / ultrasonography. Bile Duct Neoplasms / ultrasonography. Bile Ducts, ... MeSH-minor] Adenoma, Liver Cell / diagnosis. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / radiography. Carcinoma ... MeSH-minor] Adenoma, Liver Cell / ultrasonography. Bile Duct Neoplasms / ultrasonography. Bile Ducts, Intrahepatic. Carcinoma, ...
Two types of hepatic adenoma have been identified, including tumors of bile duct origin and tumors of liver cell origin. ... Hepatic adenoma is a rare, benign tumor of the liver. ... Hepatic adenomas of bile duct origin are usually smaller than 1 ... encoded search term (Hepatocellular Adenoma (Hepatic Adenoma) Imaging) and Hepatocellular Adenoma (Hepatic Adenoma) Imaging ... Two types of hepatic adenoma have been identified: tumors of bile duct origin and tumors of liver cell origin. ...
Tubulovillous Adenoma Colon or Rectum. Zenkers Diverticulum. Esophageal Stricture. Common Bile Duct Stones. ... gallbladder and bile ducts.. *Laparoscopic Surgery - Simple cases like weight loss, hernias and gallbladder problems as well as ...
What is cholangiocellular adenoma? Meaning of cholangiocellular adenoma medical term. What does cholangiocellular adenoma mean? ... Looking for online definition of cholangiocellular adenoma in the Medical Dictionary? cholangiocellular adenoma explanation ... pertaining to the bile ducts.. cholangiocellular adenoma. solid or cystic; may be neoplastic or congenital or acquired cystic ... a variety of bile duct adenoma in which the tumor is composed of multilocular cystic structures lined with epithelium ...
Resolution of Bile Duct Adenoma over Follow-up Period; A Case Report. ...
Gut microbiota, bile acid metabolism, and cytokines have not been ... ... a type of bile duct cancer, has a high mortality rate. ... Adenoma, Bile Duct. A benign tumor of the intrahepatic bile ... Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, ... in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis ...
Resolution of Bile Duct Adenoma over Follow-up Period; A Case Report. ...
Hepatic Adenoma. *Hepatic Cysts. *Bile Duct Hamartomas. *Biliary Cystadenoma. *Hepatic Abscess. *Hepatocellular Carcinoma ... Pathways of Bile Acid Synthesis From Cholesterol. *Defects in Bile Acid Synthesis Causing Metabolic Liver Disease and Syndromes ... 2: Bile Acids and Bile Flow: New Functions of Old Molecules. *Introduction ...
Progressive inflammation and fibrosis of large intra and extra hepatic bile ducts ... Along with bile duct adenoma. 6 Liver cell adenoma more common in ...
These are classified as liver cell adenomas or bile duct adenomas. In addition, a third type of tumor occurs. This lesion is ... MIXED ADENOMA (HAMARTOMA) OF THE LIVER: REPORT OF A CASE(MIXED ADENOMA (HAMARTOMA) OF THE LIVER: REPORT OF A CASE*) ROBERT M. ... MIXED ADENOMA (HAMARTOMA) OF THE LIVER: REPORT OF A CASE(MIXED ADENOMA (HAMARTOMA) OF THE LIVER: REPORT OF A CASE*). Ann Intern ... Primary benign liver tumors may arise from either the liver cells or the bile duct epithelium. ...
Bile duct adenoma Focal nodular hyperplasia Hemangioma Hepatocellular adenoma Am I Correct?. ... Benign bile duct adenomas are rare, inconsequential, and usually detected incidentally. They are sometimes mistaken for ... Hepatocellular adenoma. Hepatocellular adenoma is the most important benign tumor to recognize. It occurs primarily in women of ... Adenomas due to contraceptive use may regress if the contraceptive is stopped. If the adenoma does not regress or if it is ...
Bile duct adenoma Focal nodular hyperplasia Hemangioma Hepatocellular adenoma Am I Correct?. ...
... bile duct adenoma; biliary papillomatosis; Clonorchis sinensis infection; and Thorotrast (thorium dioxide) exposure.38-39 The ... Craig J, Peters R, Edmondson H. Tumors of the liver and intrahepatic bile ducts. In: Hartman H, Sobin L, eds. Atlas of Tumor ... Unlike fibrolamellar HCC, the central scar in FNH is not a true scar, but represents a confluence of blood vessels, bile ducts ... Hepatic adenoma. Although the precise pathogenic mechanism leading to hepatic adenomas is still unknown, the use of estrogen- ...
Diseases associated with S100A4 include Follicular Adenoma and Bile Duct Adenocarcinoma. Among its related pathways are Ca, ...
Adrenal Adenoma. *Adrenal Nodule. *Axillary Abscess. *Bile Duct Obstruction. *Biliary Colic. *Choledocholithiasis ...
... are also known as hepatic adenomas or liver cell adenomas. They are rare, benign tumors of presumable epithelial origin and ... Hepatic adenomas consist of sheets of hepatocytes without bile ducts or portal areas. Kupffer cells, if present, are reduced in ... Hepatocellular adenomas (HCAs) are also known as hepatic adenomas or liver cell adenomas. They are rare, benign tumors of ... encoded search term (Hepatocellular Adenoma) and Hepatocellular Adenoma What to Read Next on Medscape. Related Conditions and ...
  • Bile acids are a group of acidic steroids produced in the liver, stored in the gall bladder, and secreted into the intestine to aid in the digestion of dietary lipids, where 90% to 95% are reabsorbed through enterohepatic recirculation ( 1 ). (aacrjournals.org)
  • In general, the examination of bile, and of pancreatic or duodenal fluid aspirates, has been disappointing because cellular preservation is often poor, relatively few malignancies are identified, and occasional false positive results have been described. (bmj.com)
  • GB like symptoms.US-distal dilation of CBD 7.7mm.MRCP-mild prominence of pancreatic duct.Dense adhesions between GB & abdominal wall. (healthtap.com)
  • Unfortunately, bile duct cancer is very aggressive, with metastasis (spreading of the disease) occurring in about 80 percent of both dogs and cats. (mercola.com)
  • Sadly, even with successful surgery and little to no metastasis of the cancer throughout the pet's body, the prognosis for pets with bile duct cancer is very poor. (mercola.com)
  • However, UDCA failed to show efficacy to prevent the development of colorectal adenomas in a large, phase III, randomized, placebo-controlled trial. (aacrjournals.org)
  • Our findings support the use of UDCA for preventing advanced colorectal adenomas in men. (aacrjournals.org)
  • Three variants are known to exist, FAP and attenuated FAP (originally called hereditary flat adenoma syndrome ) are caused by APC gene defects on chromosome 5 while autosomal recessive FAP (or MYH-associated polyposis ) is caused by defects in the MUTYH gene on chromosome 1. (wikipedia.org)